Canopy Growth Corporation · TSX:WEED
Canopy Growth — Investor Presentation (February 2025)
23 slides from Canopy Growth's investor presentation, February 2025
Slide 1: Investor Presentation February 2025
INVESTOR PRESENTATION February 2025
Slide 2: Disclaimers and Cautionary Statements: Forward-Looking Information (1/4)
DISCLAIMERS AND CAUTIONARY STATEMENTS Forward-Looking Information (1/4) Unless otherwise noted or the context indicates otherwise, references in this presentation (this “Presentation”) to the “Company,” “Canopy Growth,” “we,” “us” and “our” refer to Canopy Growth Corporation and its direct and indir
Slide 3: Disclaimers and Cautionary Statements: Forward-Looking Information (2/4)
DISCLAIMERS AND CAUTIONARY STATEMENTS Forward-Looking Information (2/4) our ability to successfully create and launch brands and further create, launch and scale products in jurisdictions where such products are legal and that we currently operate in; the benefits, viability, safety, efficacy, dosin
Slide 4: Disclaimers and Cautionary Statements: Forward-Looking Information (3/4)
DISCLAIMERS AND CAUTIONARY STATEMENTS Forward-Looking Information (3/4) The forward-looking statements contained herein are based upon certain material assumptions, including: (i) management’s perceptions of historical trends, current conditions and expected future developments; (ii) our ability to
Slide 5: Disclaimers and Cautionary Statements: Forward-Looking Information (4/4)
DISCLAIMERS AND CAUTIONARY STATEMENTS Forward-Looking Information (4/4) risks related to the integration of acquired businesses; the timing and manner of the legalization of cannabis in the United States; business strategies, growth opportunities and expected investment; counterparty risks and liqui
Slide 6: Disclaimers and Cautionary Statements: Website References
DISCLAIMERS AND CAUTIONARY STATEMENTS Website References References to information included on, or accessible through, websites do not constitute incorporation by reference of the information contained at or available through such websites, and you should not consider such information to be part of
Slide 7: Non-GAAP Measures
NON-GAAP MEASURES “Adjusted EBITDA” is a non-GAAP measure used by management that is not defined by U.S. GAAP and may not be comparable to similar measures presented by other companies. Management believes that Adjusted EBITDA is a useful measure for investors because it provides meaningful and usef
Slide 8: Canopy Growth: Positioned for sustainable cannabis market leadership
Canopy Growth: Positioned for sustainable cannabis market leadership Dedication to unleashing the power of Cannabis centered cannabis in key markets Industry-leading brands and products Brand & Consumer-led rooted in consumer preferences Global reach with A $70B CAD market opportunity by 20281 North
Slide 9: Cannabis Centered: Delivering the Benefits of Cannabis to Consumers and Patients Globally
Cannabis Centered: Delivering the Benefits of Cannabis to Consumers and Patients Globally Canopy Growth is dedicated to being a leader in the cannabis sector with disciplined and measured investment in emerging markets Core Canada: International: Storz & Bickel: Leading Investment Medical + Adult-Us
Slide 10: Global Opportunity: CAD $70B+ Legal Cannabis Market Opportunity by 2028
Global Opportunity: CAD $70B+ Legal CANNABIS MARKET OPPORTUNITY BY 2028 Driven by Gaining Consumer Acceptance 1 $70 61 $60 57 53 $50 49 44 CAD $ Billions $40 Market Sizing $30 $20 $10 6 7 7 7 7 1 1 1 1 1 $- 2024 2025 2026 2027 2028 Canada USA Int'l (Germany, Poland, Czechia, ANZ) Includes both medic
Slide 11: Canada Cannabis
CANADA CANNABIS • Canada cannabis net revenue was $41MM in Q3 FY2025, representing an increase of 1% compared to Q3 FY2024. Canada cannabis net revenue in Q3 FY2025 increased 10% sequentially compared to Q2 FY2025. • Canada medical cannabis net revenue in Q3 FY2025 increased 16% compared to Q3 FY202
Slide 12: International Markets
INTERNATIONAL MARKETS • International markets net revenue was $12MM in Q3 FY2025, representing an increase of 14% over Q3 FY2024, with strong growth in Poland and Germany, partially offset by a decline in Australia medical cannabis sales as well as exiting US CBD sales earlier this fiscal year. • Pe
Slide 13: Storz & Bickel
STORZ & BICKEL ® • Storz & Bickel delivered net revenue in Q3 FY2025 of $22MM, representing a 19% increase over Q3 FY2024 driven by traditionally strong holiday purchases, robust direct-to-consumer online sales, and continued growth in Germany. • Continued robust consumer demand drove strong year-ov
Slide 14: Canopy USA: Leading Premium-Focused Brand Powerhouse
has been Canopy USA 1: Leading Premium-Focused Brand Powerhouse WANA2 - gummies Jetty3 - extracts ACREAGE4 - MSO TERRASCEND5 - MSO An innovative North American Authentic vape experience and Vertical integration from Vertical integration in in PA, NJ, cannabis edibles brand award-winning technology c
Slide 15: Q3 FY2025 Financial Results
Q3 FY2025 FINANCIAL RESULTS
Slide 16: Q3 FY2025 Key Financial Highlights
Q3 FY2025 KEY FINANCIAL HIGHLIGHTS (CDN in vs. • Net revenue in Q3 FY2025 decreased 5% compared to Q3 FY2024. Excluding net revenue from businesses divested during the twelve months ended millions) Q3 FY2025 Q3 FY2024 March 31, 2024, net revenue increased 8%. Net Revenue $75 (5%) • Consolidated gros
Slide 17: Revenue Performance by Channel
REVENUE PERFORMANCE BY CHANNEL1 vs. (in millions of Canadian dollars, unaudited) Q3 FY2025 Q3 FY2024 Canada Adult Cannabis Net Revenue2 $21.2 (9%) Canada Medical Cannabis Net Revenue3 $19.6 16% $40.8 1% International Markets cannabis4 $12.0 14% Storz & Bickel $22.0 19% Other - (100%) Net Revenue $74
Slide 18: Gross Margin Performance
GROSS MARGIN PERFORMANCE Drivers of Q3 FY2025 Gross Margin Year-over-Year Change By Consolidated Gross Margin Performance Reported Segment Consolidated (-) The decline in Canada Cannabis segment, primarily Canada Cannabis Gross Margin 40% Gross Margin attributable to lower adult-use sales and costs
Slide 19: Free Cash Flow and Debt
FREE CASH FLOW AND DEBT Free Cash Flow1 Total Debt Balance ($CAD’MM) ($CAD’MM) - Q2 FY24 Q2 FY25 700 612 597 (5) 600 561 554 (10) 500 442 (15) 400 (20) 300 (25) (30) (28) 200 (35) (34) 100 (40) - Q3 FY24 Q3 FY25 Q3 FY24 Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Free cash flow from continuing operations of Red
Slide 20: Appendix
APPENDIX
Slide 21: Adjusted EBITDA (Non-GAAP) Reconciliation
ADJUSTED EBITDA1 (NON-GAAP) RECONCILIATION
Slide 22: Free Cash Flow (Non-GAAP) Reconciliation
FREE CASH FLOW1 (NON-GAAP) RECONCILIATION
Slide 23: Thank You
THANK YOU 23
Canopy Growth — Investor Presentation (February 2025) on 6ix